Citations

Showing 10 of 108104 citations.

Pivotal phase III COMPOSE trial will compare 177 Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors.
Reidy‐Lagunes, Diane , Vijayvergia, Namrata , Goldstein, Grace , Michael, Michael , Leyden, Simone , Öberg, Kjell E., Sierras, Cristina, Harris, Philip J. , Hálfdánarson, Þorvarður R. , Halperin, Daniel M. , Kong, Grace , Grozinsky‐Glasberg, Simona , Sørbye, Halfdan , Harris, Philip

Mayo Clinic

Journal of Clinical Oncology | January 19, 2022 | Volume: 40 | Issue: 4_suppl | Pages: TPS514-TPS514

10.1200/jco.2022.40.4_suppl.tps514 Get It

TPS514 Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), which represent approximately 70% of NETs, frequently develop metastatic disease with limited treatment options. Current standard therapies for well-differentiated high grade 2 and grade 3 GEP-NETs include cytoreductive procedures, somatostatin analogues, molecular targeted therapies (everolimus or sunitinib), chemotherapy and peptide receptor radionuclide therapy (PRRT), with no specified sequence of use. PRRT may stabilize disease and induce objective tumor responses. This treatment uses radiolabeled somatostatin analogues to selectively target somatostatin receptor expressing (SSTR+) tumor cells. 177 Lu-edotreotide is an innovative radiolabeled somatostatin analogue with a favorable safety profile and promising efficacy. Retrospective data in metastatic GEP-NETs treated with two or more 177 Lu-edotreotide cycles demonstrated a progression free survival (PFS) of at least 30 months. The currently recruiting Phase III COMPETE trial compares the efficacy and safety of 177 Lu-edotreotide, versus everolimus, in grade 1 and grade 2 GEP-NETs. Methods: COMPOSE (NCT04919226) is a prospective, randomized, controlled, open-label, multi-center Phase III study, in patients with well-differentiated high grade 2 and grade 3 (Ki-67 index 15−55%), SSTR+, GEP-NETs. This trial is to evaluate the efficacy, safety and patient-reported outcomes of first- or second-line treatment with 177 Lu-edotreotide PRRT compared to best standard of care. It aims to randomize 202 patients 1:1 to a defined number of cycles of 177 Lu-edotreotide or an active comparator (either chemotherapy [CAPTEM or FOLFOX] or everolimus, according to investigator´s choice). The primary endpoint is PFS, assessed every 12 weeks until disease progression (RECIST v1.1), or death, whichever occurs earlier. Secondary outcomes include overall survival, assessed up to 2 years after disease progression. Study recruitment for COMPOSE commenced in September 2021. It is expected that COMPOSE will inform optimal treatment options for patients with well-differentiated high grade 2 and grade 3 SSTR+ GEP-NETs, including for first-line therapy. Clinical trial information: NCT04919226.
Risk factors for long-term hip osteoarthritis in patients with hip dysplasia without surgical intervention
Melugin, Heath P. , Hale, Rena F. , Lee, Dustin R., LaPrade, Matthew D. , Okoroha, Kelechi R. , Trousdale, Robert T. , Levy, Bruce A. , Krych, Aaron J. , Krych, Aaron J , Sierra, Rafael J.

Mayo Clinic

Journal of Hip Preservation Surgery | January 19, 2022 | Volume: 9 | Issue: 1 | Pages: 18-21

10.1093/jhps/hnac007 | PMID 35651707 Get It

ABSTRACT Hip dysplasia is a common cause of hip pain and a known risk factor for hip osteoarthritis (OA) and early total hip arthroplasty (THA). Unfortunately, little is known about the specific factors associated with an increased risk of OA. The purpose was (i) to report the overall rate of symptomatic hip OA and THA and (ii) to identify radiographic features and patient characteristics associated with the development of symptomatic hip OA. A geographic database was used to identify all patients aged 14–50 years old diagnosed with symptomatic hip dysplasia between 2000 and 2016. Kaplan–Meier analysis was used to determine the rate of symptomatic hip OA, defined as a Tönnis grade of ≥1 on hip radiograph. Univariate and multivariate proportional hazard regression models were performed to determine risk factors for OA. One hundred and fifty-nine hips (144 patients) with hip dysplasia (52 F:107 M) out of 1893 patients with hip pain were included. Of these, 45 (28%) had severe hip dysplasia with a lateral center-edge angle ≤18°. Mean age at time of presentation was 26.1 (±10.1) years. Mean follow-up time was 8.2 (±5) years. The rate of OA was 20%. THA was performed in 11% of patients. Body mass index >29 (P = 0.03) and increased age (P < 0.01) were risk factors for OA. Patients with symptomatic hip dysplasia are at significant risk of developing hip OA. Body mass index >29 and age ≥35 years at the time of presentation with hip pain were risk factors for hip OA.
Book review of An Introduction to MRI for Medical Physicists and Engineers
Hu, Yanle

Mayo Clinic

Journal of Applied Clinical Medical Physics | January 19, 2022 | Volume: 23 | Issue: 3 | Pages: No page available

10.1002/acm2.13435 Get It

The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
Ma, Cynthia X., Luo, Jingqin , Freedman, Rachel A., Pluard, Timothy , Nangia, Julie R., Lu, Janice, Valdez-Albini, Frances, Cobleigh, Melody, Jones, Jason M., Lin, Nancy U. , Thomas, Shana, Anderson, Jill, Haas, Brittney, Bucheit, Leslie, Bryce, Richard , Lalani, Alshad S., Gao, Feng, Kimmick, Gretchen, Pegram, Mark D. , Bose, Ron , Cobleigh, Melody , Kimmick, Gretchen , Pluard, Timothy J , Winer, Eric , Marcom, Paul Kelly , Bryce, Richard , Carey, Lisa A , Goetz, Matthew P , Pegram, Mark D , Ellis, Matthew J , Bose, Ron , Lin, Nancy U , Luo, Jingqin , Ma, Cynthia X., Freedman, Rachel A., Nangia, Julie R., Lu, Janice, Valdez-Albini, Frances, Jones, Jason M., Thomas, Shana, Anderson, Jill, Haas, Brittney, Bucheit, Leslie, Lalani, Alshad S., Gao, Feng

Mayo Clinic

Clinical Cancer Research | January 19, 2022 | Volume: 28 | Issue: 7 | Pages: 1258-1267

10.1158/1078-0432.ccr-21-3418 | PMID 35046057 Get It

Abstract Purpose: HER2 mutations (HER2mut) induce endocrine resistance in estrogen receptor–positive (ER+) breast cancer. Patients and Methods: In this single-arm multi-cohort phase II trial, we evaluated the efficacy of neratinib plus fulvestrant in patients with ER+/HER2mut, HER2 non-amplified metastatic breast cancer (MBC) in the fulvestrant-treated (n = 24) or fulvestrant-naïve cohort (n = 11). Patients with ER-negative (ER−)/HER2mut MBC received neratinib monotherapy in an exploratory ER− cohort (n = 5). Results: The clinical benefit rate [CBR (95% confidence interval)] was 38% (18%–62%), 30% (7%–65%), and 25% (1%–81%) in the fulvestrant-treated, fulvestrant-naïve, and ER− cohorts, respectively. Adding trastuzumab at progression in 5 patients resulted in three partial responses and one stable disease ≥24 weeks. CBR appeared positively associated with lobular histology and negatively associated with HER2 L755 alterations. Acquired HER2mut were detected in 5 of 23 patients at progression. Conclusions: Neratinib and fulvestrant are active for ER+/HER2mut MBC. Our data support further evaluation of dual HER2 blockade for the treatment of HER2mut MBC.
First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy
Diamond, Jennifer R. , Lim, Emerson A. , Nowakowski, Grzegorz S. , Valencia, Ray , Genvresse, Isabelle , Merz, Claudia , Boix, Oliver , Frigault, Melanie M. , Greer, Joy M., Hamdy, Ahmed , Huang, Xin , Moreno, Víctor , Boni, Valentina , Lim, Emerson , Boix, Oliver , Izumi, Raquel , Moreno, Victor , Córdoba, Raúl , Morillo, Daniel , Wong, Harvey

Mayo Clinic

Clinical Cancer Research | January 19, 2022 | Volume: 28 | Issue: 7 | Pages: 1285-1293

10.1158/1078-0432.ccr-21-3617 | PMID 35046056 Get It

Abstract Purpose: To report on the first-in-human phase I study of VIP152 (NCT02635672), a potent and highly selective cyclin-dependent kinase 9 (CDK9) inhibitor. Patients and Methods: Adults with solid tumors or aggressive non–Hodgkin lymphoma who were refractory to or had exhausted all available therapies received VIP152 monotherapy as a 30-minute intravenous, once-weekly infusion, as escalating doses (5, 10, 15, 22.5, or 30 mg in 21-day cycles) until the MTD was determined. Results: Thirty-seven patients received ≥ 1 VIP152 dose, with 30 mg identified as the MTD based on dose-limiting toxicity of grade 3/4 neutropenia. The most common adverse events were nausea and vomiting (75.7% and 56.8%, respectively), all of grade 1/2 severity. Of the most common events, grade 3/4 events occurring in > 1 patient were neutropenia (22%), anemia (11%), abdominal pain (8%), increased alkaline phosphatase (8%), and hyponatremia (8%). Day 1 exposure for the MTD exceeded the predicted minimum therapeutic exposure and reproducibly achieved maximal pathway modulation; no accumulation occurred after multiple doses. Seven of 30 patients with solid tumors had stable disease (including 9.5 and 16.8 months in individual patients with pancreatic cancer and salivary gland cancer, respectively), and 2 of 7 patients with high-grade B-cell lymphoma with MYC and BCL2/BCL6 translocations (HGL) achieved durable complete metabolic remission (ongoing at study discontinuation, after 3.7 and 2.3 years of treatment). Conclusions: VIP152 monotherapy, administered intravenously once weekly, demonstrated a favorable safety profile and evidence of clinical benefit in patients with advanced HGL and solid tumors.
Comparison of Cosyntropin, Vigabatrin, and Combination Therapy in New-Onset Infantile Spasms in a Prospective Randomized Trial
Knupp, Kelly G. , Coryell, Jason , Singh, Rani K. , Gaillard, William D. , Shellhaas, Renée A. , Koh, Sookyong , Mitchell, Wendy G. , Harini, Chellamani , May, Alison S., Dlugos, Dennis , Nickels, Katherine , Mytinger, John R. , Keator, Cynthia, Yozawitz, Elissa , Singhal, Nilika S. , Lockrow, Jason , Lockrow, Jason , Shellhaas, Renée A , Gaillard, William D , Yozawitz, Elissa G , Nickels, Katherine C , Knupp, Kelly G , Coryell, Jason , Millichap, J Gordon , Thomas, Jacob F. , Juarez‐Colunga, Elizabeth

Mayo Clinic

Journal of Child Neurology | January 19, 2022 | Volume: 37 | Issue: 3 | Pages: 186-193

10.1177/08830738211073400 | PMID 35044272 Get It

Objective: In a randomized trial, we aimed to evaluate the efficacy of cosyntropin injectable suspension, 1 mg/mL, compared to vigabatrin for infantile spasms syndrome. An additional arm was included to assess the efficacy of combination therapy (cosyntropin and vigabatrin) compared with cosyntropin monotherapy. Methods: Children (2 months to 2 years) with new-onset infantile spasms syndrome and hypsarhythmia were randomized into 3 arms: cosyntropin, vigabatrin, and cosyntropin and vigabatrin combined. Daily seizures and adverse events were recorded, and EEG was repeated at day 14 to assess for resolution of hypsarhythmia. The primary outcome measure was the composite of resolution of hypsarhythmia and absence of clinical spasms at day 14. Fisher exact test was used to compare outcomes. Results: 37 children were enrolled and 34 were included in the final efficacy analysis (1 withdrew prior to treatment and 2 did not return seizure diaries). Resolution of both hypsarhythmia and clinical spasms was achieved in in 9 of 12 participants (75%) treated with cosyntropin, 1/9 (11%) vigabatrin, and 5/13 (38%) cosyntropin and vigabatrin combined. The primary comparison of cosyntropin versus vigabatrin was significant (64% [95% confidence interval 21, 82], P < .01). Adverse events were reported in all 3 treatment arms: 31 (86%) had an adverse event, 7 (19%) had a serious adverse event, and 15 (42%) had an adverse event of special interest with no difference between treatment arms. Significance: This randomized trial was underpowered because of incomplete enrollment, yet it demonstrated that cosyntropin was more effective for short-term outcomes than vigabatrin as initial treatment for infantile spasms.
The Turtle Neck Sign: Identification of Severe Retracted Distal Biceps Tendon Rupture
Boonrod, Artit , Harasymczuk, Michał , Ramazanian, Taghi , Boonrod, Arunnit, Smith, Jay , O’Driscoll, Shawn W. , Fitzsimmons, James S

Mayo Clinic

Orthopaedic Journal of Sports Medicine | January 19, 2022 | Volume: 10 | Issue: 1 | Pages: No page available

10.1177/23259671211065030 | PMID 35071656 Get It

Background: Chronic tendon retraction subsequent to distal biceps tendon rupture significantly increases repair difficulty and potential for tendon grafting. Biceps tendons that appear short or absent with magnetic resonance imaging (MRI) or that cannot be readily identified at surgery may erroneously be classified as irreparable. These apparent “absent” biceps tendons may actually be retracted and curled up inside the muscle, visually resembling the head-neck of a turtle retracted inside its shell (the “turtle neck sign”). When located, these tendons could be unfolded and repaired primarily. This type of tendon retraction seems to be associated with high-degree ruptures and larcertus fibrosus tears. Purpose: To test the hypothesis that tendon retractions with a turtle neck sign on MRI are more associated with high-degree ruptures and larcertus fibrosus tears versus tendon tears with simple linear retraction. Study Design: Cross-sectional study; Level of evidence, 3. Methods: Retracted distal biceps tendon ruptures on sagittal MRI were categorized as linear retraction or curled-up (turtle neck) retraction. Retraction length, injury severity, and lacertus fibrosus tears were analyzed. Results: The authors retrospectively analyzed the patient records of 85 consecutive traumatic distal biceps tendon ruptures from 2003 to 2019; the final study cohort was 37 patients. Injury-to-surgery timing was as follows: <3 weeks, 43% (16 cases); 3 weeks to 3 months, 32% (12 cases); and >3 months, 24% (9 cases). Overall, 19 patients had linear retraction <7 cm (mean, 3.3 ± 1.9 cm) and 18 patients had a turtle neck retraction ≥7 cm (mean, 9.1 ± 1.6 cm). The injury-to-surgery time (median [± interquartile range]) was 27 days (±90 days) in the linear retraction group and 23 days (±65 days) in the turtle neck retraction group. The turtle neck retraction group had a significantly higher occurrence of abnormal hook test findings, complete distal biceps tendon rupture, and lacertus fibrosus tears compared with the linear retraction group (100% vs 58%, 100% vs 68%, and 100% vs 37%, respectively; P ≤ .02). However, significant repairability differences were not found. Conclusion: Highly retracted distal biceps turtle neck sign tendon ruptures occur frequently in association with high-degree ruptures and lacertus fibrosus tears. The presence of a turtle neck retraction did not affect reparability. Surgeons should be aware of this curled-up retraction to avoid mistaking it for an absent tendon or a muscle-tendon disruption.
Neuropathological Findings of CSF1R‐Related Leukoencephalopathy After Long‐Term Immunosuppressive Therapy
Koga, Shunsuke , Tipton, Philip W. , Wierenga, Klaas J. , Koga, Shunsuke , Tipton, Philip W , Dickson, Dennis W. , Wszołek, Zbigniew K.

Mayo Clinic

Movement Disorders | January 19, 2022 | Volume: 37 | Issue: 2 | Pages: 439-440

10.1002/mds.28919 | PMID 35044689 Get It

Outcomes of Pyrocarbon Arthroplasty in Metacarpophalangeal Joints Affected by Rheumatoid Arthritis
Cummings, Paige , Mohney, Brian G. , Rizzo, Marco , Cummings, Paige E , Claxton, Matthew R , Rizzo, Marco , Wagner, Eric R.

Mayo Clinic

HAND | January 19, 2022 | Volume: 18 | Issue: 6 | Pages: 931-937

10.1177/15589447211063577 | PMID 35043719 Get It

Background: Rheumatoid arthritis (RA) affecting the metacarpophalangeal (MCP) joint may warrant arthroplasty. The purpose of this study was to investigate implant survivorship, complications, radiographic outcomes, and clinical outcomes in patients undergoing MCP arthroplasty with a pyrocarbon implant to treat RA. Methods: In all, 124 MCP joint pyrocarbon arthroplasties in 40 patients performed to treat RA were reviewed. Operations were at the index (n = 43, 35%), middle (n = 33, 27%), ring (n = 27, 22%), and small (n = 21, 17%) fingers from 1998 to 2009 in 105 (85%) female and 19 (15%) male joints with a mean age of 54 ± 11 years. Mean postoperative follow-up was 6 ± 3 years. All patients achieved at least 2 years of follow-up. Results: Rates of implant survivorship at 1, 2, 5, and 10 years were 98%, 98%, 90%, and 81%, respectively. Fifteen percent (n = 18) of arthroplasties underwent revision at a mean 5 ± 3 years postoperatively. The overall reoperation rate was 29% (n = 36). Rates of survival from reoperation at 1, 2, 5, and 10 years were 85%, 84%, 76%, and 68%, respectively. Complications occurred in 32% (n = 40). Pain ratings improved postoperatively ( P < .01). Arc of motion improved from 37 ± 21 to 43 ± 19 ( P = .03). Both appositional and oppositional strength improved after surgery; however, there was no improvement in grip strength ( P < .01). Conclusions: Metacarpophalangeal arthroplasty with a pyrocarbon implant demonstrated reliable improvement in pain and arc of motion in patients with RA. Complication and overall reoperation rates were high, while 1 in 10 undergo revision within 5 years postoperatively.
Considerations for the Use of Phage Therapy in Clinical Practice
Suh, Gina A. , Lodise, Thomas P. , Tamma, Pranita D. , Knisely, Jane M., Alexander, Jose, Aslam, Saima, Barton, Karen D., Bizzell, Erica, Totten, Katherine M. C. , Campbell, Joseph L., Chan, Benjamin K., Cunningham, Scott A., Goodman, Katherine E., Greenwood-Quaintance, Kerryl E., Harris, Anthony D., Hesse, Shayla , Maresso, Anthony, Nussenblatt, Veronique, Pride, David , Rybak, Michael J. , Sund, Zoe, Tyne, Daria Van , Patel, Robin , Group, for the Antibacterial Resistance Leadership, Barton, Karen D. , van Duin, David , Van Tyne, Daria , Patel, Robin , Tamma, Pranita D , Suh, Gina A , Lodise, Thomas P. , Knisely, Jane M., Alexander, Jose, Aslam, Saima, Bizzell, Erica, Totten, Katherine M. C. , Campbell, Joseph L., Chan, Benjamin K., Cunningham, Scott A., Goodman, Katherine E., Greenwood-Quaintance, Kerryl E., Harris, Anthony D., Hesse, Shayla , Maresso, Anthony, Nussenblatt, Veronique, Pride, David , Rybak, Michael J , Sund, Zoe, Group, for the Antibacterial Resistance Leadership

Mayo Clinic

Antimicrobial Agents and Chemotherapy | January 18, 2022 | Volume: 66 | Issue: 3 | Pages: No page available

10.1128/aac.02071-21 | PMID 35041506 Get It

Increasing antimicrobial resistance and medical device-related infections have led to a renewed interest in phage therapy as an alternative or adjunct to conventional antimicrobials. Expanded access and compassionate use cases have risen exponentially but have varied widely in approach, methodology, clinical situations in which phage therapy might be considered, dosing, route of administration, and outcomes.